Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy.
Maysa M Abu-KhalafAnton SafonovJamie StrattonShiyi WangChristos HatzisEsther ParkLajos PusztaiCary P GrossRaymond RussellPublished in: Breast cancer research and treatment (2019)
Age, preexisting cardiac risk factors and coronary artery disease did not predict a baseline abnormal LVEF. While the prevalence of an abnormal baseline LVEF is low in patients with breast cancer, our results suggest that cardiac screening prior to anthracycline is cost-effective.
Keyphrases
- left ventricular
- risk factors
- coronary artery disease
- patients undergoing
- heart failure
- hypertrophic cardiomyopathy
- aortic stenosis
- acute myocardial infarction
- cardiac resynchronization therapy
- left atrial
- percutaneous coronary intervention
- cardiovascular events
- stem cells
- type diabetes
- mesenchymal stem cells
- transcatheter aortic valve replacement